Business
Exicure Announces Appointment of Dr. Douglas E. Feltner as Chief Medical Officer
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical
About this update from Exicure, Inc.
[{"type":"text","content":" CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nExicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that it has appointed Douglas E. Feltner, M.D. as its Chief Medical Officer effective May 18th, 2020. Dr. Feltner joins Exicure from AveXis (now part of Novartis) where he was the Vice President of Clinical Development, focusing on developing gene therapies for neurodegenerative and neurodevelopmental disorders, including the recent approval of Zolgensma™ for patients with Spinal Muscular Atrophy.\n\n\n“Doug brings deep experience in all phases of drug development, starting with translational and early strategic decision making all the way to phase 3 registration trials. Exicure is committed to building a growing pipeline of neurological drug candidates and we are very pleased to have Doug bring his expertise and experience to this important initiative,” stated Dr. David Giljohann, CEO of Exicure.\n\n\nDr. Feltner is a physician-scientist, with over 20 years of experience in clinical drug development and in translational medicine, primarily focused on neurology, psychiatry and neuroscience. Prior to AveXis, Dr. Feltner, served as Vice President, Neuroscience Development, for AbbVie, Inc. and Vice President, Global Head of Translational Medicine for Pfizer, Inc. Dr. Feltner earned his M.D., with distinction in research, from the University of Michigan Medical School, did his residency in psychiatry at George Washington University, and was a postdoctoral fellow in the Lab of Mammalian Genes and Development at The National Institute of Child Health and Human Development.\n\n\nDr. Feltner commented, “I have watched with great interest the development of Exicure’s spherical nucleic acid technology. I see many compelling opportunities for addressing unmet neurological conditions with Exicure’s SNA platform technology and am thrilled to join their growing team.”\n\n\nAbout Exicure’s Neurological Programs\n\n\nExicure has conducted extensive preclinical research evaluating the suitability of our SNA technology for genetically defined neurological diseases, including efficacy studies in animal models, and biodistribution in rodent and non-human primates. Our pre-clinical work suggests that the SNA platform may be well-suited for developm...